Curis (CRIS) Amortizatization of Intangibles (2010 - 2024)
Curis' (CRIS) quarterly Amortizatization of Intangibles came in at -$428000.0 in Q4 2024, down 2953.33% YoY from $15000.0 in Q1 2024, and down 7033.33% on a QoQ basis from -$6000.0 in Q3 2024.
Curis (CRIS) Amortizatization of Intangibles (2010 - 2024) Analysis & Trends
Curis (CRIS) has 15 years of Amortizatization of Intangibles data on file, last reported at -$428000.0 in Q4 2024.
- Quarterly Amortizatization of Intangibles fell 2953.33% year-over-year to -$428000.0 in Q4 2024, while the trailing twelve-month figure through Sep 2025 was -$428000.0 (down 193.25% YoY) and the FY2024 annual result came in at $16000.0, down 98.49% from the prior year.
- Amortizatization of Intangibles eased to -$428000.0 in Q4 2024, from -$6000.0 in the prior quarter.
- In the past five years, Amortizatization of Intangibles ranged from a high of $534000.0 in Q2 2024 to a low of -$439000.0 in Q2 2021.
- A 5-year average of -$35550.0 and a median of -$15500.0 in 2020 frame the typical range for Amortizatization of Intangibles.
- Annual changes were most pronounced in 2021 — Amortizatization of Intangibles tumbled 19550.0% — and 2023, when it soared 681.58%.
- Tracing CRIS's Amortizatization of Intangibles over 5 years: stood at $2000.0 in 2020, then plunged by 19550.0% to -$389000.0 in 2021, then soared by 177.12% to $300000.0 in 2022, then tumbled by 95.0% to $15000.0 in 2023, then sank by 2953.33% to -$428000.0 in 2024.
- The last three Amortizatization of Intangibles figures came in at -$428000.0 (Q4 2024), -$6000.0 (Q3 2024), and $534000.0 (Q2 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 678,000.00 |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Curis | 3.27 Mn | -2.35 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -428,000.00 |
| Dec 31, 2024 | -428,000.00 |
| Sep 30, 2024 | -6,000.00 |
| Sep 30, 2024 | -6,000.00 |
| Jun 30, 2024 | 534,000.00 |
| Jun 30, 2024 | 534,000.00 |
| Mar 31, 2024 | -84,000.00 |
| Mar 31, 2024 | -84,000.00 |
| Dec 31, 2023 | 15,000.00 |
| Dec 31, 2023 | 15,000.00 |
| Sep 30, 2023 | 442,000.00 |
| Sep 30, 2023 | 442,000.00 |
| Jun 30, 2023 | 457,000.00 |
| Jun 30, 2023 | 457,000.00 |
| Mar 31, 2023 | 145,000.00 |
| Mar 31, 2023 | 145,000.00 |
| Dec 31, 2022 | 300,000.00 |
| Dec 31, 2022 | 300,000.00 |
| Sep 30, 2022 | -76,000.00 |
| Sep 30, 2022 | -76,000.00 |